Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

Chiara Mignogna, Nicoletta Staropoli, Cirino Botta, Carmela De Marco, Antonia Rizzuto, Michele Morelli, Annalisa Di Cello, Renato Franco, Caterina Camastra, Ivan Presta, Natalia Malara, Angela Salvino, Pierfrancesco Tassone, Pierosandro Tagliaferri, Tullio Barni, Giuseppe Donato, Anna Di Vito

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment.

Original languageEnglish
Article number31
JournalJournal of Ovarian Research
Volume9
Issue number1
DOIs
Publication statusPublished - May 21 2016

Fingerprint

Aurora Kinase A
Platinum
Carcinoma
Drug Therapy
Precision Medicine
Therapeutics
Paclitaxel
Patient Selection
Retrospective Studies
Salts

Keywords

  • AURKA
  • High-grade serous ovarian carcinoma (HGSOC)
  • Platinum
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. / Mignogna, Chiara; Staropoli, Nicoletta; Botta, Cirino; De Marco, Carmela; Rizzuto, Antonia; Morelli, Michele; Di Cello, Annalisa; Franco, Renato; Camastra, Caterina; Presta, Ivan; Malara, Natalia; Salvino, Angela; Tassone, Pierfrancesco; Tagliaferri, Pierosandro; Barni, Tullio; Donato, Giuseppe; Di Vito, Anna.

In: Journal of Ovarian Research, Vol. 9, No. 1, 31, 21.05.2016.

Research output: Contribution to journalArticle

Mignogna, C, Staropoli, N, Botta, C, De Marco, C, Rizzuto, A, Morelli, M, Di Cello, A, Franco, R, Camastra, C, Presta, I, Malara, N, Salvino, A, Tassone, P, Tagliaferri, P, Barni, T, Donato, G & Di Vito, A 2016, 'Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients', Journal of Ovarian Research, vol. 9, no. 1, 31. https://doi.org/10.1186/s13048-016-0238-7
Mignogna, Chiara ; Staropoli, Nicoletta ; Botta, Cirino ; De Marco, Carmela ; Rizzuto, Antonia ; Morelli, Michele ; Di Cello, Annalisa ; Franco, Renato ; Camastra, Caterina ; Presta, Ivan ; Malara, Natalia ; Salvino, Angela ; Tassone, Pierfrancesco ; Tagliaferri, Pierosandro ; Barni, Tullio ; Donato, Giuseppe ; Di Vito, Anna. / Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. In: Journal of Ovarian Research. 2016 ; Vol. 9, No. 1.
@article{54712bad96a64f3c90f631422ed687ff,
title = "Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients",
abstract = "High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 {\%} of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment.",
keywords = "AURKA, High-grade serous ovarian carcinoma (HGSOC), Platinum, Prognosis, Therapy",
author = "Chiara Mignogna and Nicoletta Staropoli and Cirino Botta and {De Marco}, Carmela and Antonia Rizzuto and Michele Morelli and {Di Cello}, Annalisa and Renato Franco and Caterina Camastra and Ivan Presta and Natalia Malara and Angela Salvino and Pierfrancesco Tassone and Pierosandro Tagliaferri and Tullio Barni and Giuseppe Donato and {Di Vito}, Anna",
year = "2016",
month = "5",
day = "21",
doi = "10.1186/s13048-016-0238-7",
language = "English",
volume = "9",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients

AU - Mignogna, Chiara

AU - Staropoli, Nicoletta

AU - Botta, Cirino

AU - De Marco, Carmela

AU - Rizzuto, Antonia

AU - Morelli, Michele

AU - Di Cello, Annalisa

AU - Franco, Renato

AU - Camastra, Caterina

AU - Presta, Ivan

AU - Malara, Natalia

AU - Salvino, Angela

AU - Tassone, Pierfrancesco

AU - Tagliaferri, Pierosandro

AU - Barni, Tullio

AU - Donato, Giuseppe

AU - Di Vito, Anna

PY - 2016/5/21

Y1 - 2016/5/21

N2 - High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment.

AB - High-Grade Serous Ovarian Carcinoma (HGSOC) is the predominant histotype of epithelial ovarian cancer (EOC), characterized by advanced stage at diagnosis, frequent TP53 mutation, rapid progression, and high responsiveness to platinum-based-chemotherapy. To date, standard first-line-chemotherapy in advanced EOC includes platinum salts and paclitaxel with or without bevacizumab. The major prognostic factor is the response duration from the end of the platinum-based treatment (platinum-free interval) and about 10-0 % of EOC patients bear a platinum-refractory disease or develop early resistance (platinum-free interval shorter than 6 months). On these bases, a careful selection of patients who could benefit from chemotherapy is recommended to avoid unnecessary side effects and for a better disease outcome. In this retrospective study, an immunohistochemical evaluation of Aurora Kinase A (AURKA) was performed on 41 cases of HGSOC according to platinum-status. Taking into account the number and intensity of AURKA positive cells we built a predictive score able to discriminate with high accuracy platinum-sensitive patients from platinum-resistant patients (p < 0.001). Furthermore, we observed that AURKA overexpression correlates to worse overall survival (p = 0.001; HR 0.14). We here suggest AURKA as new effective tool to predict the biological behavior of HGSOC. Particularly, our results indicate that AURKA has a role both as predictor of platinum-resistance and as prognostic factor, that deserves further investigation in prospective clinical trials. Indeed, in the era of personalized medicine, AURKA could assist the clinicians in selecting the best treatment and represent, at the same time, a promising new therapeutic target in EOC treatment.

KW - AURKA

KW - High-grade serous ovarian carcinoma (HGSOC)

KW - Platinum

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84969560249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969560249&partnerID=8YFLogxK

U2 - 10.1186/s13048-016-0238-7

DO - 10.1186/s13048-016-0238-7

M3 - Article

C2 - 27209210

AN - SCOPUS:84969560249

VL - 9

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 31

ER -